Related Experiment Videos
Increased plasma decay-accelerating factor levels in paroxysmal nocturnal hemoglobinuria
H Nakakuma1, S Nagakura, T Kawaguchi
1Second Department of Internal Medicine, Kumamoto University Medical School, Japan.
International Journal of Hematology
|April 1, 1992
Summary
Plasma levels of decay-accelerating factor (DAF) are significantly elevated in paroxysmal nocturnal hemoglobinuria (PNH) patients. Measuring soluble DAF may aid in PNH diagnosis and monitoring disease progression.
Area of Science:
- Biochemistry
- Immunology
- Hematology
Background:
- Decay-accelerating factor (DAF) is a complement regulatory protein.
- DAF deficiency is characteristic of paroxysmal nocturnal hemoglobinuria (PNH) on blood cells.
- The role and structure of soluble DAF in body fluids are not fully understood.
Purpose of the Study:
- To investigate the clinical and pathological significance of soluble DAF.
- To quantify plasma DAF levels in PNH patients and healthy individuals.
Main Methods:
- Development of a quantitative enzyme-linked immunosorbent assay (ELISA) for soluble DAF.
- Measurement of plasma DAF concentrations using the developed ELISA.
Main Results:
- Plasma DAF levels were significantly higher in PNH patients (258 +/- 150 ng/ml) compared to healthy controls (80 +/- 41 ng/ml).
- The ELISA assay demonstrated a measurable range of 0.2-12 ng for soluble DAF.
Conclusions:
- Elevated plasma DAF levels are associated with PNH.
- Plasma DAF measurement can be a valuable tool for PNH clinical diagnosis.
- Soluble DAF levels may help quantitatively assess clonal expansion in PNH.